CA-SD-ASSOCIATION
19.5.2020 14:02:05 CEST | Business Wire | Press release
The SD Association announced today the SD 8.0 Specification for SD Express memory cards receives even faster transfer speeds by using the popular PCI Express® (PCIe® ) 4.0 specification delivering a maximum of nearly 4 gigabytes per second (GB/s) data transfer rate. These full sized cards continue to use the NVMe Express™ (NVMe™) upper layer protocol enabling advanced memory access mechanism. As always SD Express memory cards using SD 8.0 specification maintain backward compatibility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005027/en/
“SD Express’ use of even faster PCIe and NVMe architectures to deliver faster transfer speeds creates more opportunities for devices to use SD memory cards,” said Mats Larsson, Senior Market Analyst at Futuresource. “This combination of trusted and well-known technologies makes it easier for future product designs to leverage the benefits of removable storage in new ways.”
SD Express gigabyte speeds bring new storage opportunities for devices with demanding performance levels, across a variety of industries. The cards can move large amounts of data generated by data-intense wireless or wired communication, super-slow motion video, RAW continuous burst mode and 8K video capture and playback, 360 degree cameras/videos, speed hungry applications running on cards and mobile computing devices, ever evolving gaming systems, multi-channel IoT devices and automotive to name a few. SD Express will be offered on SDHC, SDXC and SDUC memory cards.
“By dramatically increasing the speeds for SD Express we’re giving device manufacturers and system developers more storage choices,” said Hiroyuki Sakamoto, SDA president. “SD 8.0 may open even more opportunities for extra high performance solutions using removable memory cards.”
“PCI-SIG® is pleased to see that SDA is continuing to adopt even faster PCIe technology configurations using PCIe 4.0 interface and dual lanes for one of the top leading removable memory cards – SD,” said Al Yanes, PCI-SIG president and chairman. “PCIe specification conformance tests are available today by major test vendors, offering a significant advantage for any new PCIe technology adopter.”
“NVMe is the industry-recognized performance SSD interface from the client to the datacenter, shipping in millions of units,” said Amber Huffman, NVM Express™ Inc. president. “Consumers will benefit by SD Association continuing the adoption of the NVMe base specification for their latest SD Express cards.”
SD Express uses the well-known PCIe 4.0 specification and the latest NVMe specification (up to version 1.4) defined by PCI-SIG and NVM Express, respectively. SD 8.0 specification provides two transfer speed options for SD Express memory cards. The two transfer speeds are accomplished by supporting either PCIe 3.0 x2 or PCIe 4.0 x1 architectures with up to ~2GB/s and with PCIe 4.0 x2 technology with up to 4GB/s. SD Express cards offering PCIe 4.0 x1 architecture use the same form factor as defined for SD 7.0 specification cards with a second row of pins to deliver transfer speeds up to 2 GB/s. SD Express cards supporting dual PCIe lanes (PCIe 3.0 x2 or PCIe 4.0 x2 technologies) have three rows of pins.
The SDA makes adoption of SD Express easy allowing companies to use existing test equipment and saving in product development costs. The SD 8.0 specification continues giving system developers access to PCIe and NVMe technologies, such as Bus Mastering, Multi Queue (without locking mechanism) and Host Memory Buffer.
Two revised white papers, “SD Express Cards with PCIe and NVMe Interfaces ,” and “SD Express and microSD Express Memory Cards: The Best Choice for Your Future Product Designs ” provide an in-depth look at the opportunities created by SD Express. More information is available on our website .
Visit the SDA Virtual Tradeshow to learn more about SD Express solutions offered by our members.
SD Association
The SD Association is a global ecosystem of nearly 900 technology companies charged with setting interoperable SD standards. The Association encourages the development of consumer electronic, wireless communication, digital imaging and networking products that utilize market-leading SD technology. The SD standard is the number one choice for consumers and has earned more than 80 percent of the memory card market with its reliable interoperability and its easy-to-use format. Today, smart phones, tablets, drones, IoT devices, HDTVs, audio players, automotive systems, computers, digital cameras and digital video cameras feature SD interoperability. For more information about SDA or to join, please visit the Association’s website, https://www.sdcard.org .
SD Logos are trademarks licensed by SD-3C LLC.
PCI-SIG
PCI-SIG is the consortium that owns and manages PCI specifications as open industry standards. The organization defines industry standard I/O (input/output) specifications consistent with the needs of its members. Currently, PCI-SIG is comprised of nearly 800 industry-leading member companies. To learn more about PCI-SIG, and for a list of the Board of Directors, visit www.pcisig.com . PCI Express® is a registered trademark of PCI-SIG.
About NVM Express, Inc.
With more than 100 members, NVM Express is a non-profit organization focused on enabling broad ecosystem adoption of high performance and low latency non-volatile memory (NVM) storage through a standards-based approach. The organization offers an open collection of NVM Express (NVMe™) specifications and information to fully expose the benefits of non-volatile memory in all types of computing environments from mobile to data center. NVMe-based specifications are designed from the ground up to deliver high bandwidth and low latency storage access for current and future NVM technologies. For more information, visit http://www.nvmexpress.org .
PCIe® - PCI Express, is a standard developed by PCI-SIG® and PCIe® is a trademark owned by PCI-SIG.
NVMe™ - NVM ExpressTM , is a standard developed by NVM Express Inc. and NVMe™ is a trademark owned by NVM Express Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200519005027/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom